Pictet Asset Management Holding SA Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Pictet Asset Management Holding SA raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 27.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,969 shares of the biopharmaceutical company’s stock after acquiring an additional 3,431 shares during the period. Pictet Asset Management Holding SA’s holdings in Catalyst Pharmaceuticals were worth $333,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CPRX. Vanguard Group Inc. grew its position in Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after acquiring an additional 390,116 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 5.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Boston Partners boosted its holdings in shares of Catalyst Pharmaceuticals by 1.3% in the 4th quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock worth $27,325,000 after purchasing an additional 16,601 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock valued at $26,023,000 after purchasing an additional 79,182 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Catalyst Pharmaceuticals by 80.3% during the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock valued at $15,364,000 after buying an additional 327,936 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on CPRX. Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Stephens restated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Trading Down 5.7 %

Shares of NASDAQ:CPRX opened at $21.45 on Friday. The company has a 50-day moving average price of $22.65 and a 200-day moving average price of $21.99. The company has a market cap of $2.61 billion, a price-to-earnings ratio of 18.18, a price-to-earnings-growth ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $26.16.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.